A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients with Hypereosinophilic Syndrome (HES) - NATRON

Study identifier:D3254C00001

ClinicalTrials.gov identifier:NCT04191304

EudraCT identifier:2019-002039-27

CTIS identifier:2023-510455-28-00

Recruitment Complete

Official Title

A Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled, 24-Week Phase III Study with an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab in Patients with Hypereosinophilic Syndrome (HES)

Medical condition

Hypereosinophilic Syndrome

Phase

Phase 3

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

117

Study type

Interventional

Age

12 Years - 130 Years

Date

Study Start Date: 20 Jul 2020
Estimated Primary Completion Date: 02 May 2025
Estimated Study Completion Date: 23 Apr 2027

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Feb 2025 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria